Phase II study on weekly bolus topotecan in advanced or recurrent cervical cancer

D. Lorusso, S. Mainenti, A. Pietragalla, E. Fusco, P. Malaguti, V. Masciullo, G. Scambia

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Objective: It was the aim of our study to evaluate the efficacy and safety of weekly topotecan in patients with advanced or recurrent cervical disease. Methods: Topotecan was administered intravenously as a weekly infusion at a dose of 3.5 mg/m2 on days 1, 8 and 15 of a 28-day cycle. After the second cycle, the dose was increased to 4 mg/m2 if no grade >2 toxicity occurred. Treatment was continued until disease progression or unacceptable toxicity. Results: Twenty-one patients were enrolled, but only 18 were evaluable for response and toxicity. Ten patients (56%) had received primary surgery + chemoradiation, 6 patients (33%) had previously received surgery + chemotherapy and 2 patients (11%) exclusive chemoradiation. Patients received a mean of 3.5 courses (range 1-6). No complete or partial responses were reported. Two patients (11%) presented disease stabilization as maximum response. Median progression-free survival was 11 weeks (95% CI 15-25), and median overall survival was 28 weeks (95% CI 24-72). The treatment was generally well tolerated. Conclusions: This trial did not report any activity of weekly bolus topotecan in the treatment of advanced or recurrent cervical cancer. Actually, there is no evidence to recommend this therapy in this patient population.

Original languageEnglish
Pages (from-to)390-394
Number of pages5
JournalOncology
Volume80
Issue number5-6
DOIs
Publication statusPublished - Aug 2011

Fingerprint

Topotecan
Uterine Cervical Neoplasms
Therapeutics
Disease-Free Survival
Disease Progression
Safety
Drug Therapy
Survival

Keywords

  • Cervical cancer
  • Chemotherapy
  • Topotecan

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Lorusso, D., Mainenti, S., Pietragalla, A., Fusco, E., Malaguti, P., Masciullo, V., & Scambia, G. (2011). Phase II study on weekly bolus topotecan in advanced or recurrent cervical cancer. Oncology, 80(5-6), 390-394. https://doi.org/10.1159/000330537

Phase II study on weekly bolus topotecan in advanced or recurrent cervical cancer. / Lorusso, D.; Mainenti, S.; Pietragalla, A.; Fusco, E.; Malaguti, P.; Masciullo, V.; Scambia, G.

In: Oncology, Vol. 80, No. 5-6, 08.2011, p. 390-394.

Research output: Contribution to journalArticle

Lorusso, D, Mainenti, S, Pietragalla, A, Fusco, E, Malaguti, P, Masciullo, V & Scambia, G 2011, 'Phase II study on weekly bolus topotecan in advanced or recurrent cervical cancer', Oncology, vol. 80, no. 5-6, pp. 390-394. https://doi.org/10.1159/000330537
Lorusso D, Mainenti S, Pietragalla A, Fusco E, Malaguti P, Masciullo V et al. Phase II study on weekly bolus topotecan in advanced or recurrent cervical cancer. Oncology. 2011 Aug;80(5-6):390-394. https://doi.org/10.1159/000330537
Lorusso, D. ; Mainenti, S. ; Pietragalla, A. ; Fusco, E. ; Malaguti, P. ; Masciullo, V. ; Scambia, G. / Phase II study on weekly bolus topotecan in advanced or recurrent cervical cancer. In: Oncology. 2011 ; Vol. 80, No. 5-6. pp. 390-394.
@article{9074a6703f7a45cba4cdd857b6700c24,
title = "Phase II study on weekly bolus topotecan in advanced or recurrent cervical cancer",
abstract = "Objective: It was the aim of our study to evaluate the efficacy and safety of weekly topotecan in patients with advanced or recurrent cervical disease. Methods: Topotecan was administered intravenously as a weekly infusion at a dose of 3.5 mg/m2 on days 1, 8 and 15 of a 28-day cycle. After the second cycle, the dose was increased to 4 mg/m2 if no grade >2 toxicity occurred. Treatment was continued until disease progression or unacceptable toxicity. Results: Twenty-one patients were enrolled, but only 18 were evaluable for response and toxicity. Ten patients (56{\%}) had received primary surgery + chemoradiation, 6 patients (33{\%}) had previously received surgery + chemotherapy and 2 patients (11{\%}) exclusive chemoradiation. Patients received a mean of 3.5 courses (range 1-6). No complete or partial responses were reported. Two patients (11{\%}) presented disease stabilization as maximum response. Median progression-free survival was 11 weeks (95{\%} CI 15-25), and median overall survival was 28 weeks (95{\%} CI 24-72). The treatment was generally well tolerated. Conclusions: This trial did not report any activity of weekly bolus topotecan in the treatment of advanced or recurrent cervical cancer. Actually, there is no evidence to recommend this therapy in this patient population.",
keywords = "Cervical cancer, Chemotherapy, Topotecan",
author = "D. Lorusso and S. Mainenti and A. Pietragalla and E. Fusco and P. Malaguti and V. Masciullo and G. Scambia",
year = "2011",
month = "8",
doi = "10.1159/000330537",
language = "English",
volume = "80",
pages = "390--394",
journal = "Oncology",
issn = "0030-2414",
publisher = "UBM Medica Healthcare Publications",
number = "5-6",

}

TY - JOUR

T1 - Phase II study on weekly bolus topotecan in advanced or recurrent cervical cancer

AU - Lorusso, D.

AU - Mainenti, S.

AU - Pietragalla, A.

AU - Fusco, E.

AU - Malaguti, P.

AU - Masciullo, V.

AU - Scambia, G.

PY - 2011/8

Y1 - 2011/8

N2 - Objective: It was the aim of our study to evaluate the efficacy and safety of weekly topotecan in patients with advanced or recurrent cervical disease. Methods: Topotecan was administered intravenously as a weekly infusion at a dose of 3.5 mg/m2 on days 1, 8 and 15 of a 28-day cycle. After the second cycle, the dose was increased to 4 mg/m2 if no grade >2 toxicity occurred. Treatment was continued until disease progression or unacceptable toxicity. Results: Twenty-one patients were enrolled, but only 18 were evaluable for response and toxicity. Ten patients (56%) had received primary surgery + chemoradiation, 6 patients (33%) had previously received surgery + chemotherapy and 2 patients (11%) exclusive chemoradiation. Patients received a mean of 3.5 courses (range 1-6). No complete or partial responses were reported. Two patients (11%) presented disease stabilization as maximum response. Median progression-free survival was 11 weeks (95% CI 15-25), and median overall survival was 28 weeks (95% CI 24-72). The treatment was generally well tolerated. Conclusions: This trial did not report any activity of weekly bolus topotecan in the treatment of advanced or recurrent cervical cancer. Actually, there is no evidence to recommend this therapy in this patient population.

AB - Objective: It was the aim of our study to evaluate the efficacy and safety of weekly topotecan in patients with advanced or recurrent cervical disease. Methods: Topotecan was administered intravenously as a weekly infusion at a dose of 3.5 mg/m2 on days 1, 8 and 15 of a 28-day cycle. After the second cycle, the dose was increased to 4 mg/m2 if no grade >2 toxicity occurred. Treatment was continued until disease progression or unacceptable toxicity. Results: Twenty-one patients were enrolled, but only 18 were evaluable for response and toxicity. Ten patients (56%) had received primary surgery + chemoradiation, 6 patients (33%) had previously received surgery + chemotherapy and 2 patients (11%) exclusive chemoradiation. Patients received a mean of 3.5 courses (range 1-6). No complete or partial responses were reported. Two patients (11%) presented disease stabilization as maximum response. Median progression-free survival was 11 weeks (95% CI 15-25), and median overall survival was 28 weeks (95% CI 24-72). The treatment was generally well tolerated. Conclusions: This trial did not report any activity of weekly bolus topotecan in the treatment of advanced or recurrent cervical cancer. Actually, there is no evidence to recommend this therapy in this patient population.

KW - Cervical cancer

KW - Chemotherapy

KW - Topotecan

UR - http://www.scopus.com/inward/record.url?scp=79961103215&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79961103215&partnerID=8YFLogxK

U2 - 10.1159/000330537

DO - 10.1159/000330537

M3 - Article

VL - 80

SP - 390

EP - 394

JO - Oncology

JF - Oncology

SN - 0030-2414

IS - 5-6

ER -